One application covers Eliquis and Sotyktu

One document serves both, and it covers additional Bristol Myers Squibb products beyond these two, so a practice filing for one is already familiar with the form for the others.

Each product is a separate enrollment for the patient even though the form is shared, and the prescriber certifies the specific drug.

Eliquis volume is what makes this matter. Anticoagulation panels are large, and a practice filing constantly for Eliquis has effectively already trained for Sotyktu.

Products filed on this Bristol Myers Squibb application
BrandGenericUsed forHow it is given
Eliquisapixabanreducing stroke risk in non-valvular atrial fibrillation and treating or preventing venous thromboembolismDispensed to the patient, usually through a pharmacy
Sotyktudeucravacitinibmoderate-to-severe plaque psoriasisDispensed to the patient, usually through a pharmacy

Eligibility factors to verify

Bristol Myers Squibb sets the eligibility criteria for the Eliquis and Sotyktu program and changes them, so the categories below are only the ones programs of this kind generally assess.They are not the criteria for this program, confirm current requirements onBristol Myers Squibb’s official program pagebefore telling a patient anything. We do not publish income thresholds for Eliquis and Sotyktu here, because a stale number on a marketing page is how a practice ends up telling a patient the wrong thing.

  • Insurance status, generally aimed at patients who are uninsured, or insured but unable to access the medication through their coverage.
  • Household income against the program’s own published threshold, evidenced by documentation rather than attestation.
  • Residency and prescriber licensure requirements set by the program.
  • A prescription written for an indication the program covers, certified by the prescribing clinician.

What the application needs

A complete Eliquis and Sotyktu application is assembled from the four parts below, and because Eliquis and Sotyktu is dispensed to the patient, usually through a pharmacy, the part most likely to hold it up is the one this practice controls least. Missing any one of them is what sends a form back rather than forward.

Components of a Eliquis and Sotyktu patient assistance application
PartWho owns itWhat it contains
Prescriber sectionPrescribing clinicianDiagnosis, treatment plan, prescribed regimen, prescriber credentials and NPI, and the certification signature.
Patient sectionPatient or verified legal representativeDemographics, contact and shipping details, insurance status, household information, program consent and the patient’s signature.
Income documentationPatientDocumentary evidence of household income, in whichever forms the program accepts.
Program-specific attachmentsPracticeWhatever else this specific program requires. Requirements differ between programs and change over time.

Where practices get stuck

Common workflow challenges for these programs:

  • Volume is the defining problem on the Eliquis side: anticoagulation panels are large and the same program runs constantly, so the bottleneck is the queue rather than any individual form.
  • An interruption in anticoagulation carries immediate clinical risk, so a stalled application is not merely a paperwork problem.
  • Many Eliquis patients are older adults for whom a coverage gap is the trigger for applying, so circumstances have to be checked against the program rather than assumed.
  • Sotyktu is newer, so staff are less familiar with it despite the form being one they already use. The unfamiliarity is with the drug, not the document.
  • Sotyktu patients often reach it after topicals and at least one systemic therapy, which means prior-treatment history has to be assembled from the chart.

How long an application takes

We do not publish a turnaround figure for Eliquis and Sotyktu, because Bristol Myers Squibb sets it and it moves. What a practice can control is the work before submission. Four factors commonly affect the timeline: how long the patient section takes to return, how many review cycles occur between staff and the prescriber, whether the submission is complete on the first attempt, and the manufacturer review time, which we do not estimate.

How AlgoMeds handles it for Eliquis and Sotyktu

AlgoMeds opens the correct current Eliquis form, including variant forms that depend on indication, already filled from the patient chart, prescriber profile, insurance on file and prior submitted applications. The patient signs from a single-use, identity-verified link sent by text message, with no account required. This can reduce printing and scanning. Required documents are checked before submission, the application is tracked to a decision, and renewals open ahead of expiry using information from the prior application.

For Eliquis and Sotyktu, as for every program, AlgoMeds does not determine eligibility, predict approval, or claim to improve the odds of a decision going a particular way. It removes the paperwork between a clinical decision and a submittedEliquis and Sotyktu application, nothing more, and nothing that touches the manufacturer’s judgement.See the full coordinator workflow.

Eliquis and Sotyktu patient assistance: frequently asked questions

Does the same Bristol Myers Squibb form cover other products too?

The foundation uses one enrollment form across several products in its range, of which Eliquis and Sotyktu are two. Each product is still its own enrollment for the patient. Confirm the current product list on the official program page.

What makes high-volume assistance programs different to run?

The bottleneck stops being the individual form and becomes the queue. Pinned frequently-used programs, autofill from the record, and a tracked next action per application are what scale.

Related program guides

Practices working with this program may also work with these programs. See the full program directory, or thecardiometabolic overview.

Written by the AlgoMeds Editorial Team · editorial checks by AlgoMeds Editorial ReviewOfficial source verified: · verification policyProgram details are subject to change without notice.

Eliquis and Sotyktu are registered trademarks of Bristol Myers Squibb or its affiliates. AlgoMeds is not affiliated with, endorsed by, or sponsored by Bristol Myers Squibb. Program details are subject to change. Confirm current requirements with the official program before applying.

This page is general information for medical practices about a manufacturer program. It is not medical advice, not legal advice, and not a determination of eligibility. AlgoMeds does not host or reproduce manufacturer enrollment forms on this website.

Stop retyping the Eliquis form.

Supported fields are filled from practice records, patients can sign from a text message, and staff can track each application from one workflow.